47.50 +0.04 (0.08%)
After hours: 6:10PM EDT
|Bid||47.30 x 900|
|Ask||47.69 x 1800|
|Day's range||47.02 - 47.83|
|52-week range||42.48 - 63.69|
|Beta (3Y monthly)||0.71|
|PE ratio (TTM)||12.50|
|Forward dividend & yield||1.64 (3.49%)|
|1y target est||N/A|
Bristol-Myers Squibb Company (NYSE: BMY) today announced that the European Commission (EC) has granted unconditional approval of Bristol-Myers Squibb’s pending acquisition of Celgene Corporation (NASDAQ:CELG). “Clearance from the European Commission is an important milestone toward completing our combination with Celgene and moves us one step closer to creating a leading biopharma company that is well positioned to develop and deliver innovative, meaningful medicines to patients,” said Giovanni Caforio, M.D., Chairman and Chief Executive Officer of Bristol-Myers Squibb. Bristol-Myers Squibb intends to close the Celgene transaction at the earliest possible date, which it currently expects to be by the end of 2019 or the beginning of 2020.
Bristol-Myers Squibb Company today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion on a Type-II variation application for Empliciti plus pomalidomide and low-dose dexamethasone for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior therapies, including lenalidomide ...
NEW YORK-- -- Increases Second Quarter Revenues 10% to $6.3 Billion Posts Second Quarter GAAP EPS of $0.87 and Non-GAAP EPS of $1.18 Announces Topline Results for CheckMate-227 Part 1a and Part 2 Continues to Advance Celgene Integration Planning and Transaction Closing Updates 2019 GAAP and Non-GAAP EPS Guidance Bristol-Myers Squibb Company today reported results for the second quarter of 2019, which ...
PRINCETON, N.J.-- -- Study Met Its Co-Primary Endpoint of Overall Survival with Opdivo ® Plus Low Dose Yervoy ® vs. Chemotherapy in First-Line Non-Small Cell Lung Cancer Patients Whose Tumors Express PD-L1 ≥1% Third Tumor Type in Which Opdivo Plus Yervoy Demonstrates Overall Survival Benefit in a Phase 3 Trial Bristol-Myers Squibb Company today announced that Part 1a of the Phase 3 CheckMate -227 trial ...
PRINCETON, N.J.-- -- Study Did Not Meet Its Primary Endpoint of Overall Survival with Opdivo ® Plus Chemotherapy vs. Chemotherapy in First-Line Non-Squamous Non-Small Cell Lung Cancer Bristol-Myers Squibb Company today announced that Part 2 of the Phase 3 CheckMate -227 trial did not meet the primary endpoint of overall survival with Opdivo ® plus chemotherapy versus chemotherapy in patients with ...
WHIPPANY, N.J. & PRINCETON, N.J. & OSAKA, Japan-- -- Combination of regorafenib and nivolumab vs. regorafenib alone to be evaluated in patients with micro-satellite stable metastatic colorectal cancer Companies plan indication-seeking trial Bayer, Bristol-Myers Squibb Company and Ono Pharmaceutical Co., Ltd. announced today the three companies have entered into a clinical collaboration agreement ...
Bristol-Myers Squibb Company (BMY) announced today that effective July 1, 2019 it has completed its previously announced divestment of its consumer health business, UPSA, to Taisho Pharmaceutical Co., Ltd (Taisho), the largest over-the-counter drug company in Japan. The divestiture is part of Bristol-Myers Squibb’s strategy to simplify and to realign its business portfolio to address changes in its business and the future requirements of its evolving pipeline. UPSA is focused on delivering important consumer medicines in France, across Europe and additional countries that are outside of the Bristol-Myers Squibb core focus.
Bristol-Myers Squibb Company announced today the extension of the expiration date of the offers to exchange notes issued by Celgene Corporation for up to $19,850,000,000 aggregate principal amount of new notes to be issued by Bristol-Myers Squibb Company and cash and the related consent solicitations being made by Bristol-Myers Squibb on behalf of Celgene to adopt certain proposed amendments to the ...
Bristol-Myers Squibb Company (BMY) today provided an update on the approval process and timeline for the Company’s pending merger with Celgene Corporation (CELG). The Company remains actively engaged in discussions with the U.S. Federal Trade Commission (“FTC”) on the FTC’s continued review of the proposed transaction. To allow the transaction to close on a timely basis in light of concerns expressed by the FTC, the Company is planning the divestiture of OTEZLA® (apremilast).
Bristol-Myers Squibb Company today announced topline results from CheckMate -459, a randomized Phase 3 study evaluating Opdivo versus sorafenib as a first-line treatment in patients with unresectable hepatocellular carcinoma .
Bristol-Myers Squibb Company (BMY) and Catalent, Inc. (CTLT), today announced that Catalent has agreed to purchase Bristol-Myers Squibb’s oral solid, biologics, and sterile product manufacturing and packaging facility in Anagni, Italy. Catalent is the leading global provider of advanced delivery technologies, development and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products.
In a descriptive analysis, addition of Empliciti to pomalidomide and dexamethasone reduced risk of death by 46% among patients with RRMM
The Board of Directors of Bristol-Myers Squibb Company today declared a quarterly dividend of forty one cents per share on the $.10 par value Common Stock of the corporation.
Bristol-Myers Squibb Company (BMY) today announced data from a Phase IV mechanistic study exploring differences in the cellular and molecular mechanisms by which ORENCIA® (abatacept) and another treatment, adalimumab, interfere with disease progression in moderate-to-severe early rheumatoid arthritis (RA) patients seropositive for certain autoantibodies. Among 80 adult patients with early (≤ 12 months from symptom onset) moderate-to-severe RA who had never been treated with a biologic medication and tested positive for autoantibodies called anti-citrullinated protein antibody (ACPA) and rheumatoid factor (RF), numerically higher efficacy responses were seen with ORENCIA at week 24. ACR 20/50/70 scores for adalimumab were 63, 45 and 30, respectively.
Bristol-Myers Squibb Company will announce results for the second quarter of 2019 on Thursday, July 25, 2019. During a conference call at 10:30 a.m. ET on July 25, company executives will review financial information and will address inquiries from investors and analysts.
Bristol-Myers Squibb Company (BMY) today announced the future leadership team of the combined company effective upon completion of the company’s pending merger with Celgene Corporation (CELG). The company is evolving key aspects of its R&D and Commercialization structure to drive the continued growth of a highly successful marketed portfolio, maximize the six near-term launch opportunities and deliver the value of the combined pipeline, all guided by its continued mission of serving patients with serious disease.
Bristol-Myers Squibb Company will take part in Goldman Sachs 40th Annual Global Healthcare Conference on Tuesday, June 11, 2019, in Rancho Palos Verdes, CA. Chris Boerner, Executive Vice President, Chief Commercial Officer, will answer questions about the company at 11:00 a.m.
Five-year follow-up analysis from Phase 1 CA209-004 study provides evidence of long-term survival following discontinuation of treatment in patients with advanced melanoma
Opdivo plus Yervoy yielded objective response rate of 31% and median duration of response of 17.5 months